KLOXXADO

Peak

naloxone hcl

Hikma
NDANASALSPRAY
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

sites. Administration of naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.

Indications (1)

depression

Loss of Exclusivity

LOE Date
Aug 26, 2034
103 months away
Patent Expiry
Aug 26, 2034

Patent Records (5)

Patent #ExpiryTypeUse Code
10722510
Aug 26, 2034
Product
U-3110
10973814
Aug 26, 2034
Product
U-3110
11135155
Aug 26, 2034
Product
—
11617713
Aug 26, 2034
Product
U-3110
11628139
Aug 26, 2034
Product
U-3110
Company
Hikma
Hikma
NJ - Berkeley Heights
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers